An individual's risk level should be considered for screening of high cardiovascular disease risk, reveals a study published in The Lancet Public Health. Researchers also claim that this could be achieved without increased healthcare costs and the current 5-year screening intervals were unnecessarily frequent for low-risk individuals and insufficiently frequent for intermediate-risk individuals.
Current American Heart Association, European Society of Cardiology, and UK National Health Service guidelines recommend a 5-yearly health check interval for screening of individuals at high cardiovascular disease risk. This health check covers measurement of a variety of risk factors including systolic blood pressure, cholesterol profile, blood glucose, and smoking status.
‘Cardiovascular disease prevention through lifestyle intervention or preventive medication could be enabled more effective through individualized screening interval.’
If lifestyle interventions are inadequate to reduce the risk, the guidelines recommend primary preventive medication such as statins. However, the 5-yearly screenings are not based on direct research evidence.
"Our study shows that by optimizing the screening intervals, 8% of myocardial infarcts and strokes could be prevented without increase in health care costs. This means that during the next 20 years, in the English population aged now 40 to 64, the number of new myocardial infarcts or strokes prevented annually could reach 5000," says lead author Joni Lindbohm MD, PhD from the University of Helsinki.
The authors estimated the optimal screening interval by following development of cardiovascular disease risk in 7000 English men and women who participated in the Whitehall II study. This study measured their cardiovascular disease risk factors according to the current guidelines in 5-yearly intervals over a 22-year follow-up and collected data on cardiovascular diseases using national electronic health and death records.
Those at low risk for cardiovascular diseases spent on average 9 years in that risk category before moving to intermediate-low risk. The participants then spent on average 7 years in this next category before progressing to intermediate-high risk. However, the time spent in intermediate-high risk was only 4 years; after this, over 70% of participants progressed to the high-risk category that leads to consideration of preventive medication if lifestyle intervention is insufficient to reduce the risk.
An individualized screening interval would enable more effective cardiovascular disease prevention by means of lifestyle intervention or preventive medication, because of more timely detection of those at high risk.
"The results are promising, but national guidelines are rarely changed based on one study. The benefits of individualized screening intervals should be further studied in a randomized control trial before changing the guidelines emphasizes one of the authors, Professor Mika Kivimäki, Director of the Whitehall II study at University College London.